Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors.

PubWeight™: 1.75‹?› | Rank: Top 3%

🔗 View Article (PMID 12796031)

Published in Ann Oncol on June 01, 2003

Authors

K Nakagawa1, T Tamura, S Negoro, S Kudoh, N Yamamoto, N Yamamoto, K Takeda, H Swaisland, I Nakatani, M Hirose, R-P Dong, M Fukuoka

Author Affiliations

1: Kinki University School of Medicine, Osaka, Japan. nakagawa@med.kindai.ac.jp

Articles citing this

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer (2010) 5.82

Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood (2005) 1.37

A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer (2007) 1.36

Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther (2011) 1.35

Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer (2007) 1.33

Targeting the epidermal growth factor receptor. Br J Cancer (2004) 1.14

Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br J Cancer (2006) 1.13

Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. Drug Resist Updat (2012) 1.12

A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. Eur J Cancer (2010) 1.09

The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations. Ther Adv Med Oncol (2010) 1.05

Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib. Mol Cancer Ther (2009) 1.03

Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer - a retrospective analysis: JMTO LC03-02. BMC Res Notes (2009) 1.02

Epidermal growth factor receptor tyrosine kinase inhibitors. Br J Cancer (2004) 0.98

Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer (2004) 0.96

Tolerability of gefitinib in patients receiving treatment in everyday clinical practice. Br J Cancer (2003) 0.93

Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC). Drug Des Devel Ther (2010) 0.92

Translatability scoring in drug development: eight case studies. J Transl Med (2012) 0.89

The role of pharmacoethnicity in the development of cytotoxic and molecular targeted drugs in oncology. Yonsei Med J (2013) 0.89

Mucosal injury from targeted anti-cancer therapy. Support Care Cancer (2006) 0.88

Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme. BMC Cancer (2004) 0.88

Metabolism considerations for kinase inhibitors in cancer treatment. Expert Opin Drug Metab Toxicol (2010) 0.86

Gefitinib in non small cell lung cancer. J Biomed Biotechnol (2011) 0.86

Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence. Drug Des Devel Ther (2014) 0.85

Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation. J Nat Sci Biol Med (2016) 0.82

A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer. Oncotarget (2015) 0.81

Adaptive prediction model in prospective molecular signature-based clinical studies. Clin Cancer Res (2013) 0.78

Gefitinib and celecoxib in advanced metastatic gastrointestinal tumors: a pilot feasibility study. J Gastrointest Oncol (2014) 0.78

Evaluation of efficacy and safety of gefitinib as monotherapy in Chinese patients with advanced non-small cell lung cancer and very poor performance status. BMC Res Notes (2008) 0.77

Ileal perforation induced by acute radiation injury under gefitinib treatment. Int J Clin Oncol (2011) 0.77

A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans. AAPS J (2015) 0.76

Successful treatment of EGFR-mutated non-small cell lung cancer with reduced-dose gefitinib: A case report. Exp Ther Med (2015) 0.76

Identifying Determinants of EGFR-Targeted Therapeutic Biochemical Efficacy Using Computational Modeling. CPT Pharmacometrics Syst Pharmacol (2014) 0.76

Management of patients with advanced non-small cell lung cancer: role of gefitinib. Biologics (2010) 0.76

Pharmacokinetics of gefitinib in a patient with non-small cell lung cancer undergoing continuous ambulatory peritoneal dialysis. Case Rep Oncol (2015) 0.75

Gefitinib and Sonidegib. Hosp Pharm (2015) 0.75

Standing the test of time in Europe? Gefitinib in the treatment of non-small-cell lung cancer. Lung Cancer (Auckl) (2010) 0.75

Successful erlotinib treatment for a patient with gefitinib-related hepatotoxicity and lung adenocarcinoma refractory to intermittently administered gefitinib. Case Rep Pulmonol (2011) 0.75

Articles by these authors

A Toll-like receptor recognizes bacterial DNA. Nature (2000) 26.34

Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol (2001) 18.80

Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity (1998) 18.12

Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity (1999) 17.40

Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol (1999) 16.86

Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity (1999) 11.64

Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science (1985) 10.71

Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J (1998) 9.36

Toll-like receptors control activation of adaptive immune responses. Nat Immunol (2001) 7.54

Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med (1997) 7.12

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol (1999) 5.65

Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol (2001) 5.36

ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep (2001) 5.32

Purification to homogeneity and properties of two D-alanine carboxypeptidases I From Escherichia coli. J Biol Chem (1976) 4.66

Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J (2009) 4.63

Circadian oscillation of a mammalian homologue of the Drosophila period gene. Nature (1997) 4.44

Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination. Nature (1992) 4.43

Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J Biol Chem (1999) 4.38

Endovascular stent-graft placement for the treatment of acute aortic dissection. N Engl J Med (1999) 4.33

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol (2002) 4.25

Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface toll-like receptor 4 expression. J Immunol (2000) 4.10

ASK1 is essential for JNK/SAPK activation by TRAF2. Mol Cell (1998) 3.98

The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med (1999) 3.72

IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol (1998) 3.56

Pig cloning by microinjection of fetal fibroblast nuclei. Science (2000) 3.51

Nitric oxide-induced apoptosis in pancreatic beta cells is mediated by the endoplasmic reticulum stress pathway. Proc Natl Acad Sci U S A (2001) 3.49

Microarray fabrication with covalent attachment of DNA using bubble jet technology. Nat Biotechnol (2000) 3.38

Transformation of human leukocytes by cocultivation with an adult T cell leukemia virus producer cell line. Science (1982) 3.37

A prospective randomised study of "covered" versus "uncovered" diamond stents for the management of distal malignant biliary obstruction. Gut (2004) 3.35

Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiation. Mol Biol Cell (1999) 3.27

Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity (2001) 3.27

Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J (1999) 3.19

Tbx5 associates with Nkx2-5 and synergistically promotes cardiomyocyte differentiation. Nat Genet (2001) 3.14

Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol (2006) 3.12

High-dose intravenous gammaglobulin for Kawasaki disease. Lancet (1984) 3.10

Cutting edge: cell surface expression and lipopolysaccharide signaling via the toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages. J Immunol (2000) 3.10

Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother (1991) 3.05

CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med (2001) 3.05

Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med (1996) 2.95

Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev (1999) 2.91

The effect of zinc supplementation on pregnancy outcome. JAMA (1995) 2.87

IKK-i, a novel lipopolysaccharide-inducible kinase that is related to IkappaB kinases. Int Immunol (1999) 2.84

Caspase-1 activation of IL-1beta and IL-18 are essential for Shigella flexneri-induced inflammation. Immunity (2000) 2.81

The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J (2001) 2.78

The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem (1998) 2.71

STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line. Proc Natl Acad Sci U S A (1996) 2.64

A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol (1992) 2.58

TLR6: A novel member of an expanding toll-like receptor family. Gene (1999) 2.55

Nucleotide sequence of the PR-1 gene of Nicotiana tabacum. FEBS Lett (1987) 2.53

Ectopic expression of CHOP (GADD153) induces apoptosis in M1 myeloblastic leukemia cells. FEBS Lett (1996) 2.53

Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest (1993) 2.52

Colonoscopic diagnosis and management of nonpolypoid early colorectal cancer. World J Surg (2000) 2.51

Tumor promoter, TPA, enhances replication of HTLV-III/LAV. Virology (1986) 2.51

Execution of apoptosis signal-regulating kinase 1 (ASK1)-induced apoptosis by the mitochondria-dependent caspase activation. J Biol Chem (2000) 2.50

Evaluation of three-dimensional finite element-based deformable registration of pre- and intraoperative prostate imaging. Med Phys (2001) 2.50

Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc Natl Acad Sci U S A (1994) 2.49

Primary structure of heat-labile enterotoxin produced by Escherichia coli pathogenic for humans. J Biol Chem (1984) 2.48

Oxidative stress activates extracellular signal-regulated kinases through Src and Ras in cultured cardiac myocytes of neonatal rats. J Clin Invest (1997) 2.44

Synergy and cross-tolerance between toll-like receptor (TLR) 2- and TLR4-mediated signaling pathways. J Immunol (2000) 2.41

Differential susceptibility to the acquired immunodeficiency syndrome retrovirus in cloned cells of human leukemic T-cell line Molt-4. J Virol (1986) 2.40

Ampulla cardiomyopathy ('Takotusbo' cardiomyopathy)--reversible left ventricular dysfunction: with ST segment elevation. Jpn Circ J (2000) 2.39

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol (2012) 2.38

Spinal cord injury in a child caused by an accidental dural puncture with a single-shot thoracic epidural needle. Anesth Analg (2003) 2.38

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med (2001) 2.37

Nonmuscle myosin II-B is required for normal development of the mouse heart. Proc Natl Acad Sci U S A (1997) 2.35

Non-A, non-B hepatitis specific antibodies directed at host-derived epitope: implication for an autoimmune process. Lancet (1990) 2.35

Intraductal papillary mucinous tumors of the pancreas comprise 2 clinical subtypes: differences in clinical characteristics and surgical management. Arch Surg (1999) 2.33

The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function. J Exp Med (1999) 2.32

Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation (1996) 2.31

Vitamin A deficiency in mice causes a systemic expansion of myeloid cells. Blood (2000) 2.30

Evolutionary adaptation of plasmid-encoded enzymes for degrading nylon oligomers. Nature (1984) 2.29

Massive increases in extracellular potassium and the indiscriminate release of glutamate following concussive brain injury. J Neurosurg (1990) 2.28

Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob Agents Chemother (1994) 2.26

Mechanisms determining aerobic or anaerobic growth in the facultative anaerobe Salmonella typhimurium. Proc Natl Acad Sci U S A (1985) 2.25

Role for mitochondrial oxidants as regulators of cellular metabolism. Mol Cell Biol (2000) 2.22

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer (2008) 2.19

Folic acid safety and toxicity: a brief review. Am J Clin Nutr (1989) 2.17

Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP(2). Proc Natl Acad Sci U S A (1999) 2.15

A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis. J Med Genet (2008) 2.15

In vitro peptidoglycan polymerization catalysed by penicillin binding protein 1b of Escherichia coli K-12. FEBS Lett (1980) 2.14

Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel. Ann Oncol (2009) 2.14

Studies on antioxidants: their carcinogenic and modifying effects on chemical carcinogenesis. Food Chem Toxicol (1987) 2.14

Endotoxin-induced serum factor that stimulates gamma interferon production. Infect Immun (1989) 2.13

Follow-up study after intracranial percutaneous transluminal cerebral balloon angioplasty. AJNR Am J Neuroradiol (1998) 2.12

Simple, rapid, quantitative, and sensitive detection of telomere repeats in cell lysate by a hybridization protection assay. Clin Chem (1999) 2.11

Respiratory syncytial virus infection results in airway hyperresponsiveness and enhanced airway sensitization to allergen. J Clin Invest (1997) 2.10

Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer. Int J Clin Oncol (2001) 2.10

A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med (1997) 2.09

Activation of hepatic NKT cells and subsequent liver injury following administration of alpha-galactosylceramide. Eur J Immunol (2000) 2.09

Essential role of nuclear factor (NF)-kappaB-inducing kinase and inhibitor of kappaB (IkappaB) kinase alpha in NF-kappaB activation through lymphotoxin beta receptor, but not through tumor necrosis factor receptor I. J Exp Med (2001) 2.07

Reaction of sevoflurane and its degradation products with soda lime. Toxicity of the byproducts. Anesthesiology (1992) 2.07